We have located links that may give you full text access.
Comparative Study
Journal Article
Multicenter Study
Randomized Controlled Trial
Long-term, open-label evaluation of the safety and efficacy of telmisartan 80 mg/hydrochlorothiazide 25 mg fixed-dose combination alone or with other antihypertensive medication.
Expert Opinion on Pharmacotherapy 2009 Februrary
OBJECTIVE: To assess the safety and efficacy of long-term treatment with telmisartan 80 mg/hydrochlorothiazide 25 mg (T80/H25) fixed-dose combination (FDC) in patients who completed a previous double-blind study, in which T80/H25 provided more blood pressure (BP) reduction and produced a BP response in more patients than did T80/H12.5 FDC.
METHODS: Patients received open-label T80/H25 for 24 weeks; further antihypertensive medication was permitted. Seated trough BP was measured at weeks 0, 4, 12 and 24.
RESULTS: Primary end point (seated trough diastolic BP (DBP) control (< 90 mmHg)) was achieved in 71.4% of patients versus 52.4% at baseline (n = 639). The improvement was apparent at week 4 and sustained thereafter. In patients who received more antihypertensive medication (111/639 (17.4%)), DBP control increased from 24.8% at baseline to 58.6% at week 24. Seated trough systolic BP (SBP)/DBP were reduced from 141.0/89.0 mmHg at baseline by 4.6/3.6 mmHg by week 24. SBP response (< 140 or > or = 20 mmHg reduction from start of previous trial) and DBP response (< 90 or > or = 10 mmHg reduction from start of previous trial) increased at week 24 versus baseline from 51.8 to 69.3% and from 55.8 to 74.3%, respectively. At week 24, 110 (17.4%) patients achieved normal SBP/DBP (< 130/< 85 mmHg) and a further 24 (3.8%) patients achieved optimal SBP/DBP (< 120/< 80 mmHg). T80/H25 FDC was well tolerated; drug-related adverse events occurred in 29 (4.5%) patients.
CONCLUSION: T80/H25 provides sustained and well-tolerated additive BP control, given alone or as part of a multi-antihypertensive therapy.
METHODS: Patients received open-label T80/H25 for 24 weeks; further antihypertensive medication was permitted. Seated trough BP was measured at weeks 0, 4, 12 and 24.
RESULTS: Primary end point (seated trough diastolic BP (DBP) control (< 90 mmHg)) was achieved in 71.4% of patients versus 52.4% at baseline (n = 639). The improvement was apparent at week 4 and sustained thereafter. In patients who received more antihypertensive medication (111/639 (17.4%)), DBP control increased from 24.8% at baseline to 58.6% at week 24. Seated trough systolic BP (SBP)/DBP were reduced from 141.0/89.0 mmHg at baseline by 4.6/3.6 mmHg by week 24. SBP response (< 140 or > or = 20 mmHg reduction from start of previous trial) and DBP response (< 90 or > or = 10 mmHg reduction from start of previous trial) increased at week 24 versus baseline from 51.8 to 69.3% and from 55.8 to 74.3%, respectively. At week 24, 110 (17.4%) patients achieved normal SBP/DBP (< 130/< 85 mmHg) and a further 24 (3.8%) patients achieved optimal SBP/DBP (< 120/< 80 mmHg). T80/H25 FDC was well tolerated; drug-related adverse events occurred in 29 (4.5%) patients.
CONCLUSION: T80/H25 provides sustained and well-tolerated additive BP control, given alone or as part of a multi-antihypertensive therapy.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app